TAK - Ovid stock plunges 66% on failed studies for soticlestat
2024-06-17 09:59:01 ET
More on Ovid Therapeutics, Takeda Pharmaceutical, etc.
- Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk
- Takeda Pharmaceutical Company Limited (TAK) Fiscal Year 2023 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited 2023 Q4 - Results - Earnings Call Presentation
- Takeda seeks licensing deal for blood cancer therapy
- Pfizer, Takeda say four-year data support Adcetris as Hodgkin lymphoma treatment